Telix Pharmaceuticals' (TLX) Buy Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed its Buy rating on Telix Pharmaceuticals and set a $20.00 price target, implying approximately 84% upside from the prior close.
• Analyst sentiment remains favorable, with a consensus rating of Moderate Buy and an average price target of $20.40; Wedbush holds a $22.00 target, while RBC downgraded the stock to Sector Perform.
• Telix shares opened at $10.85 after declining 2.2%, trading between a 52-week range of $6.28 and $12.48. Several institutional investors, including Lazard and Portland Investment Counsel, recently increased their positions.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 84.33% from the stock's previous close.

A number of other research firms have also weighed in on TLX. Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. Finally, Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.40.

Telix Pharmaceuticals Trading Down 2.2%

NASDAQ:TLX opened at $10.85 on Wednesday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $12.48. The stock's 50 day simple moving average is $11.16 and its two-hundred day simple moving average is $9.87. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TLX. Lazard Asset Management LLC boosted its position in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after buying an additional 39,400 shares during the period. Portland Investment Counsel Inc. grew its stake in Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock worth $2,063,000 after acquiring an additional 138,200 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Telix Pharmaceuticals during the third quarter worth approximately $1,883,000. Private Advisor Group LLC raised its stake in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source